This Week at FDA: Senate user fee markup, Novavax briefing docs, and CDRH withdraws a PHE guidance

This Week at FDAThis Week at FDABiologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsMedical DevicesNorth AmericaPharmaceuticalsProduct LifecycleRegulatory Intelligence/Policy